Angitia Biopharmaceuticals
CA - Woodland HillsPharmaceutical
Focus: Angitia Biopharmaceuticals is a late-stage bispecific antibody company focused on musculoskeletal and neurology indications, currently advancing a pipeline targeting degenerative disc disease, osteogenesis imperfecta, and osteoporosis. The company raised $130M in Series D funding (Feb 2026) and operates from Woodland Hills, CA.
Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago
Funding Stage
SERIES C +
Open Jobs
6+2 this month
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Should You Work at Angitia Biopharmaceuticals?
AI assessmentAngitia is a high-risk, high-reward opportunity for early-stage biotech professionals seeking technical platform depth and Phase 3 visibility, but hiring freeze and pre-revenue status limit career flexibility.
Why Work Here
- Lead Phase 3 program (AGA111 in degenerative disc disease) offers near-term visibility into potential pivotal readouts and commercial inflection
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
AGA2115
Osteogenesis ImperfectaClinical Trials (3)
NCT07062588Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
Phase 2Help build intelligence for Angitia Biopharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.